Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease

被引：31

作者：

Oh, Esther S. ^{[1
,2
]}

Troncoso, Juan C. ^{[2
,3
]}

Tucker, Stina M. Fangmark ^{[2
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

来源：

NEUROMOLECULAR MEDICINE | 2008年 / 10卷 / 03期

关键词：

Alzheimer's disease; plasma; biomarker; human; transgenic mouse model of AD;

D O I：

10.1007/s12017-008-8035-0

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Amyloid plaques are composed primarily of amyloid-beta (A beta) peptides derived from proteolytic cleavage of amyloid precursor protein (APP) and are considered to play a pivotal role in Alzheimer's disease (AD) pathogenesis. Presently, AD is diagnosed after the onset of clinical manifestations. With the arrival of novel therapeutic agents for treatment of AD, there is an urgent need for biomarkers to detect early stages of AD. Measurement of plasma A beta has been suggested as an inexpensive and non-invasive tool to diagnose AD and to monitor A beta modifying therapies. However, the majority of cross-sectional studies on plasma A beta levels in humans have not shown differences between individuals with AD compared to controls. Similarly, cross-sectional studies of mouse plasma A beta have yielded inconsistent trends in different mouse models. However, longitudinal studies appear to be more promising in humans. Recently, efforts to modify plasma A beta levels using modulators have shown some promise. In this review, we will summarize the present data on plasma A beta in humans and mouse models of AD. We will discuss the potential of modulators of A beta levels in plasma, including antibodies and insulin, and the challenges associated with measuring plasma A beta. Modulators of plasma A beta may provide an important tool to optimize plasma A beta levels and may improve the diagnostic potential of this approach.

引用

页码：195 / 207

页数：13

共 135 条

[61] Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease [J].

Kulstad, J. J. ;

Green, P. S. ;

Cook, D. G. ;

Watson, G. S. ;

Reger, M. A. ;

Baker, L. D. ;

Plymate, S. R. ;

Asthana, S. ;

Rhoads, K. ;

Mehta, P. D. ;

Craft, S. .

NEUROLOGY, 2006, 66 (10) :1506-1510

[62] Amyloid-β peptides interact with plasma proteins and erythrocytes:: Implications for their quantitation in plasma [J].

Kuo, YM ;

Kokjohn, TA ;

Kalback, W ;

Luehrs, D ;

Galasko, DR ;

Chevallier, N ;

Koo, EH ;

Emmerling, MR ;

Roher, AE .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 268 (03) :750-756

[63] High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease [J].

Kuo, YM ;

Emmerling, MR ;

Lampert, HC ;

Hempelman, SR ;

Kokjohn, TA ;

Woods, AS ;

Cotter, RJ ;

Roher, AE .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (03) :787-791

[64] Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism [J].

Kuo, YM ;

Kokjohn, TA ;

Watson, MD ;

Woods, AS ;

Cotter, RJ ;

Sue, LI ;

Kalback, WM ;

Emmerling, MR ;

Beach, TG ;

Roher, AE .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03) :797-805

[65] BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions [J].

Laird, FM ;

Cai, HB ;

Savonenko, AV ;

Farah, MH ;

He, KW ;

Melnikova, T ;

Wen, HJ ;

Chiang, HC ;

Xu, GL ;

Koliatsos, VE ;

Borchelt, DR ;

Price, DL ;

Lee, HK ;

Wong, PC .

JOURNAL OF NEUROSCIENCE, 2005, 25 (50) :11693-11709

[66] Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins [J].

Lambert, MP ;

Barlow, AK ;

Chromy, BA ;

Edwards, C ;

Freed, R ;

Liosatos, M ;

Morgan, TE ;

Rozovsky, I ;

Trommer, B ;

Viola, KL ;

Wals, P ;

Zhang, C ;

Finch, CE ;

Krafft, GA ;

Klein, WL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6448-6453

[67] Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice [J].

Lemere, CA ;

Spooner, ET ;

LaFrancois, J ;

Malester, B ;

Mori, C ;

Leverone, JF ;

Matsuoka, Y ;

Taylor, JW ;

DeMattos, RB ;

Holtzman, DM ;

Clements, JD ;

Selkoe, DJ ;

Duff, KE .

NEUROBIOLOGY OF DISEASE, 2003, 14 (01) :10-18

[68] A specific amyloid-β protein assembly in the brain impairs memory [J].

Sylvain Lesné ;

Ming Teng Koh ;

Linda Kotilinek ;

Rakez Kayed ;

Charles G. Glabe ;

Austin Yang ;

Michela Gallagher ;

Karen H. Ashe .

Nature, 2006, 440 (7082) :352-357

[69] Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model [J].

Levites, Y ;

Das, P ;

Price, RW ;

Rochette, MJ ;

Kostura, LA ;

McGowan, EM ;

Murphy, MP ;

Golde, TE .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :193-201

[70] CANDIDATE GENE FOR THE CHROMOSOME-1 FAMILIAL ALZHEIMERS-DISEASE LOCUS [J].

LEVYLAHAD, E ;

WASCO, W ;

POORKAJ, P ;

ROMANO, DM ;

OSHIMA, J ;

PETTINGELL, WH ;

YU, CE ;

JONDRO, PD ;

SCHMIDT, SD ;

WANG, K ;

CROWLEY, AC ;

FU, YH ;

GUENETTE, SY ;

GALAS, D ;

NEMENS, E ;

WIJSMAN, EM ;

BIRD, TD ;

SCHELLENBERG, GD ;

TANZI, RE .

SCIENCE, 1995, 269 (5226) :973-977

← 2 3 4 5 6 7 8 9 10 11 →